MedElevator Войти в исследования
← Поиск публикаций

DOI 10.2174/0113816128504944260930051855

Медицинская библиотека · Current pharmaceutical design · 2026

UPLC-Q-TOF/MS, Network Pharmacology, and Experimental Validation Reveal the Mechanisms of Shuangbai Tablet Against Albuminuria.

Ma Xiaoqin, Hao Chenxia, Jiang Huiting, Zhang Weixia, Xia Qin, Yang Wanhua, Huang Jingjing

СтатьяПеревод пока не подготовлен

Аннотация

INTRODUCTION

Shuangbai Tablet (SBT), a traditional Chinese medicine, has demonstrated efficacy in reducing albuminuria. This study aimed to investigate the therapeutic mechanisms underlying its antialbuminuric effects.

METHODS

The phytochemicals of SBT were analyzed by UPLC-Q-TOF/MS. Subsequently, we crossvalidated the identified phytochemicals and predicted the potential targets of SBT for albuminuria by network pharmacology and molecular docking analysis. Albuminuric male Wistar rats were induced by a single tailvein injection of Adriamycin (ADR, 5 mg/kg) and orally administered SBT for 8 weeks. Then, 24-hour Urine Protein (24 h-UTP) and serum albumin were assessed, along with changes in renal function, systemic lipid metabolism, and serum COX-2 levels. Renal histopathology was evaluated by H&E staining, while the renal expressions of VEGFR-1, VEGFA, HIF-1α, NF-κB p65, ACTN-4, and podocin were assessed by immunohistochemistry and western blotting.

RESULTS

Nine core active phytochemicals of SBT targeting HIF-1α and VEGFA were identified for albuminuria treatment. Molecular docking predicted favorable binding affinities between these phytochemicals and both HIF-1α and VEGFA. In ADR-treated rats, SBT significantly reduced proteinuria (24 h-UTP: 245.1 (95% CI, 174.9 to 315.3) mg/24 h in the middle-dose SBT group vs. 585.2 (95% CI, 460.0 to 710.4) mg/24 h in the ADR group; p < 0.0001), reversed hypoalbuminemia (ALB: 24.44 (95% CI, 17.62 to 31.25) g/L vs. 9.70 (95% CI, 4.94 to 14.46) g/L; p < 0.05), ameliorated renal dysfunction and lipid metabolic disturbances, and suppressed serum COX-2 levels. Histopathological analysis showed ameliorated renal injury. SBT stabilized the decreased expressions of renal VEGFR-1, VEGFA, HIF-1α, ACTN-4, and podocin, while suppressing NF-κB p65expression.

DISCUSSION: Further functional characterization studies are warranted to validate the pharmacological effects of SBT on albuminuria.

CONCLUSION

SBT can alleviate albuminuria, inflammation, and renal injury, associated with the stabilization of HIF-1α and VEGFA expressions.

Для цитирования: Ma Xiaoqin, Hao Chenxia, Jiang Huiting, Zhang Weixia, Xia Qin, Yang Wanhua, Huang Jingjing. UPLC-Q-TOF/MS, Network Pharmacology, and Experimental Validation Reveal the Mechanisms of Shuangbai Tablet Against Albuminuria.. Current pharmaceutical design. 2026. DOI: 10.2174/0113816128504944260930051855.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.